Femasys Partners with AMI Technologies for Fertility Portfolio in Israel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy FEMY?
Femasys announced a strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel. This collaboration marks an important step in the Company's global expansion strategy and is expected to broaden international market access and drive adoption of innovative technologies, including FemaSeed as a first-line infertility treatment and FemVue for ultrasound diagnosis of tubal factors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FEMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FEMY
Wall Street analysts forecast FEMY stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.424
Low
3.00
Averages
4.75
High
6.50
Current: 0.424
Low
3.00
Averages
4.75
High
6.50
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Femasys Appoints New COO John Canning to Drive Operations
- Executive Appointment: Femasys announced the appointment of John Canning as COO, who brings over 25 years of medical device experience, having previously served as COO and CTO at Terumo Aortic, emphasizing the company's commitment to enhancing operational efficiency.
- Strategic Acquisition Expertise: Canning played a key role in the acquisition of Bolton Medical during his tenure at Terumo Aortic, and this experience is expected to bolster Femasys's competitiveness in future M&A activities, driving business expansion.
- Stock Option Incentive: The company granted Canning an option to purchase 150,000 shares at an exercise price equal to the closing price on the grant date, aiming to attract and retain executive talent while enhancing commitment to the company's long-term growth.
- Stock Price Reaction: Femasys's shares rose by 5.93%, reflecting a positive market response to the new COO appointment, indicating increased investor confidence in the company's future operations and strategic direction.
See More
Femasys Reports FY Loss with Revenue of $2.29M
- Earnings Loss: Femasys reported a FY GAAP EPS of -$0.47, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Revenue Performance: The company generated revenue of $2.29 million, which, while a positive inflow, still falls short of covering operational costs, highlighting the need for improvements in its business model sustainability.
- Cash Position: As of December 31, 2025, Femasys had approximately $9.3 million in cash and cash equivalents, but with an accumulated deficit of about $145.8 million, the company faces significant financial pressure.
- Operational Outlook: The company expects its current cash reserves to fund operations into the third quarter of 2026; however, ongoing losses and high accumulated deficits may limit future growth potential.
See More
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
FemBloc Achieves MDSAP Certification, Accelerating Global Market Expansion
- MDSAP Certification Achievement: The FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP), significantly enhancing the company's regulatory and commercial execution capabilities across key markets such as the U.S., Canada, Japan, Australia, and Brazil, which is expected to accelerate global market entry.
- Manufacturing Credibility Boost: The MDSAP certification not only enhances FemBloc's manufacturing credibility but also supports ongoing commercialization in Europe, reducing regulatory risks and providing greater operational flexibility for market expansion in high-value regions.
- Non-Surgical Solution: FemBloc is the first non-surgical permanent birth control solution that safely creates natural scar tissue in the fallopian tubes using a patented delivery system, eliminating the risks and complexities associated with traditional surgical sterilization, which is expected to significantly lower healthcare costs and improve contraceptive options for women.
- Global Market Potential: The launch of FemBloc addresses the urgent global demand for permanent contraception while providing a safer, more convenient, and cost-effective option, enhancing the company's competitiveness in underpenetrated markets and is anticipated to attract strategic partnerships to drive future growth.
See More
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Femasys Appoints New COO John Canning to Drive Operations
- Executive Appointment: Femasys announced the appointment of John Canning as COO, who brings over 25 years of medical device experience, having previously served as COO and CTO at Terumo Aortic, emphasizing the company's commitment to enhancing operational efficiency.
- Strategic Acquisition Expertise: Canning played a key role in the acquisition of Bolton Medical during his tenure at Terumo Aortic, and this experience is expected to bolster Femasys's competitiveness in future M&A activities, driving business expansion.
- Stock Option Incentive: The company granted Canning an option to purchase 150,000 shares at an exercise price equal to the closing price on the grant date, aiming to attract and retain executive talent while enhancing commitment to the company's long-term growth.
- Stock Price Reaction: Femasys's shares rose by 5.93%, reflecting a positive market response to the new COO appointment, indicating increased investor confidence in the company's future operations and strategic direction.
See More
Femasys Reports FY Loss with Revenue of $2.29M
- Earnings Loss: Femasys reported a FY GAAP EPS of -$0.47, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Revenue Performance: The company generated revenue of $2.29 million, which, while a positive inflow, still falls short of covering operational costs, highlighting the need for improvements in its business model sustainability.
- Cash Position: As of December 31, 2025, Femasys had approximately $9.3 million in cash and cash equivalents, but with an accumulated deficit of about $145.8 million, the company faces significant financial pressure.
- Operational Outlook: The company expects its current cash reserves to fund operations into the third quarter of 2026; however, ongoing losses and high accumulated deficits may limit future growth potential.
See More
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
FemBloc Achieves MDSAP Certification, Accelerating Global Market Expansion
- MDSAP Certification Achievement: The FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP), significantly enhancing the company's regulatory and commercial execution capabilities across key markets such as the U.S., Canada, Japan, Australia, and Brazil, which is expected to accelerate global market entry.
- Manufacturing Credibility Boost: The MDSAP certification not only enhances FemBloc's manufacturing credibility but also supports ongoing commercialization in Europe, reducing regulatory risks and providing greater operational flexibility for market expansion in high-value regions.
- Non-Surgical Solution: FemBloc is the first non-surgical permanent birth control solution that safely creates natural scar tissue in the fallopian tubes using a patented delivery system, eliminating the risks and complexities associated with traditional surgical sterilization, which is expected to significantly lower healthcare costs and improve contraceptive options for women.
- Global Market Potential: The launch of FemBloc addresses the urgent global demand for permanent contraception while providing a safer, more convenient, and cost-effective option, enhancing the company's competitiveness in underpenetrated markets and is anticipated to attract strategic partnerships to drive future growth.
See More
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
